A Breakthrough in Targeted Innovation

Conquering Innovation Fatigue: Now at Amazon!

Conquering Innovation Fatigue is a new book on strategy and innovation published by John Wiley & Sons. Its authors, Jeff Lindsay, Cheryl Perkins, and Mukund Karanjikar, bring decades of experience and diverse backgrounds together to reveal new insights and strategies based on understanding the personal side of innovation. See what leading experts in business and innovation say about the book.

Supporting blog: InnovationFatigue.com

Search Box

 

Latest Entries per Tag

My Top Tags

                                       

Calendar

««Nov 2009»»
SMTWTFS
1234567
891011
12
1314
15161718192021
22232425262728
2930

Mailing List

My RSS Feeds








Latest tagged entries for 'STOCKS'



Sangamo Biosciences (SGMO): A Huge Biotech Investment Opportunity

Saturday, 10 November 2007 8:04 P GMT-06
In addition to Celgene (CELG), I recommend Sangamo Biosciences for a biotech/pharma investment with huge profit potential. Sangamo has developed zinc finger protein (ZFP) technology, a transcription factor that controls the expression of DNA in the n

Endeavour Silver (EXK): Great Buy for Patient Investors

Saturday, 6 October 2007 6:27 A GMT-06
Investor Eric Hommelberg just issued a terrific report on Endeavour Silver (AMEX: EXK) explaining why they are one of his top 20 buys. They took a big hit in the August precious metals sell-off and had a slow first half of the year with reduced prod

Jason Hommel's Miningpedia: Good Resource on Mining Stocks

Saturday, 29 September 2007 6:39 P GMT-06
Jason Hommel's Miningpedia is a source of basic information about nearly 700 mining companies around the world, allowing you to lean about factors such as their primary resource, P/E, strengths and weaknesses. Very valuable for investors interes

Sangamo Biosciences (SGMO): High Potential Biotech Opportunity

Tuesday, 25 September 2007 6:41 P GMT-06
See Rob_Cos's post on SGMO at Investor Village - good information on why SGMO is one of the key biotech stocks that you should begin adding to your portfolio. It's at a high - buy on the dips. But I didn't wait for a dip before I bought
Comments/Trackback (0-1)

An Outstanding Pharmaceutical Stock: Sanofi-Aventis Begins to Soar (SNY)

Wednesday, 4 January 2006 10:51 P GMT-06
When I recommended Sanofi-Aventi again a few days ago, SNY was below 44. It's now at 46.81, up again today in double the normal volume. With a low P/E around 13, a decent dividend, and so much upside potential, it's hard to think of a better and safe

Celgene Gets FDA Approval for Revlimid: Why I Pick CELG and SNY as Great Pharmaceutical Stocks for Investing

Sunday, 1 January 2006 1:41 P GMT-06
There are two pharmaceutical stocks that I strongly encourage people to consider: Celgene and Sanofi-Aventis. Both have a pipelines of drugs that could lead to huge growth. Just a few days ago, the FDA gave approval to Revlimid, a major drug for pati


 

See All Tags